Literature DB >> 20800871

Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.

Anita Skrtić1, Petra Korać, Delfa Radić Krišto, Radmila Ajduković Stojisavljević, Davor Ivanković, Mara Dominis.   

Abstract

Notch signaling is implicated in the pathogenesis of multiple myeloma expressing high level of active Notch proteins NOTCH1 and JAGGED1 in tumor plasma cells. We investigated expression of NOTCH1 and JAGGED1 in bone marrow trephine biopsies of 80 newly diagnosed multiple myeloma and 20 monoclonal gammopathy of undetermined significance patients using immunohistochemical methods. The number of positive tumor cells was counted per 1000 tumor cells and the intensity of staining was assessed semi quantitatively. Multiple myelomas expressed NOTCH1 in 92.31% (72/78) and JAGGED1 in 92.21% (71/77) cases. NOTCH1 staining was strong in the majority of cases (59.7%), whereas JAGGED1 was predominately weak (67.6% of cases). In contrast, both markers were negative in all monoclonal gammopathy of undetermined significance cases. However, upon progression of disease from monoclonal gammopathy of undetermined significance to multiple myeloma (seen in 4 patients), analysis of the subsequent bone marrow biopsy showed weak expression of both markers in tumorous plasma cells. Immunohistochemistry results were compared with the pattern of bone marrow infiltration, plasma cell differentiation, and the presence of t(11;14)(q13,q32), t(14;16)(q32;q23),and t(4;14)(p16.3;q23) and overall survival in multiple myeloma patients. A significant correlation was found between strong NOTCH1 staining in multiple myeloma plasma cells and the diffuse type of bone marrow infiltration (P = .002) and an immature morphologic type of plasma cells (P = .043). After a median follow-up of 20.3 months, in multiple myeloma patients no difference in overall survival between NOTCH1 (P = .484) and JAGGED1 (P = .822) positive and negative cases were found. In conclusion, our results indicate importance of NOTCH1 and JAGGED1 expression in plasma cell neoplasia and a possible diagnostic value of their immunohistochemical evaluation of bone marrow infiltrates for multiple myeloma.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20800871     DOI: 10.1016/j.humpath.2010.05.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  BRCA1-mediated signaling pathways in ovarian carcinogenesis.

Authors:  Tejaswita M Karve; Xin Li; Tapas Saha
Journal:  Funct Integr Genomics       Date:  2011-09-02       Impact factor: 3.410

2.  Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma.

Authors:  Feng Chen; Alexandra Pisklakova; Ming Li; Rachid Baz; Daniel M Sullivan; Yulia Nefedova
Journal:  Cell Oncol (Dordr)       Date:  2011-10-01       Impact factor: 6.730

3.  From multi-omics integration towards novel genomic interaction networks to identify key cancer cell line characteristics.

Authors:  T J M Kuijpers; J C S Kleinjans; D G J Jennen
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

4.  Notch signaling drives multiple myeloma induced osteoclastogenesis.

Authors:  Michela Colombo; Katja Thümmler; Leonardo Mirandola; Silvia Garavelli; Katia Todoerti; Luana Apicella; Elisa Lazzari; Marialuigia Lancellotti; Natalia Platonova; Moeed Akbar; Maurizio Chiriva-Internati; Richard Soutar; Antonino Neri; Carl S Goodyear; Raffaella Chiaramonte
Journal:  Oncotarget       Date:  2014-11-15

5.  MiR-139-5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1.

Authors:  Mingxu Song; Yuan Yin; Jiwei Zhang; Binbin Zhang; Zehua Bian; Chao Quan; Leyuan Zhou; Yaling Hu; Qifeng Wang; Shujuan Ni; Bojian Fei; Weili Wang; Xiang Du; Dong Hua; Zhaohui Huang
Journal:  Protein Cell       Date:  2014-08-23       Impact factor: 14.870

6.  Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?

Authors:  Ilaria Saltarella; Maria Antonia Frassanito; Aurelia Lamanuzzi; Arianna Brevi; Patrizia Leone; Vanessa Desantis; Lucia Di Marzo; Matteo Bellone; Daniele Derudas; Domenico Ribatti; Raffaella Chiaramonte; Maria Teresa Palano; Antonino Neri; Maria Addolorata Mariggiò; Ruggiero Fumarulo; Franco Dammacco; Vito Racanelli; Angelo Vacca; Roberto Ria
Journal:  Neoplasia       Date:  2018-12-05       Impact factor: 5.715

Review 7.  Notch signaling deregulation in multiple myeloma: A rational molecular target.

Authors:  Michela Colombo; Serena Galletti; Silvia Garavelli; Natalia Platonova; Alessandro Paoli; Andrea Basile; Elisa Taiana; Antonino Neri; Raffaella Chiaramonte
Journal:  Oncotarget       Date:  2015-09-29

8.  Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.

Authors:  Michela Colombo; Serena Galletti; Gaetano Bulfamante; Monica Falleni; Delfina Tosi; Katia Todoerti; Elisa Lazzari; Leslie A Crews; Catriona H M Jamieson; Sara Ravaioli; Francesco Baccianti; Silvia Garavelli; Natalia Platonova; Antonino Neri; Raffaella Chiaramonte
Journal:  Oncotarget       Date:  2016-08-30

9.  Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance.

Authors:  Michela Colombo; Silvia Garavelli; Mara Mazzola; Natalia Platonova; Domenica Giannandrea; Raffaella Colella; Luana Apicella; Marialuigia Lancellotti; Elena Lesma; Silvia Ancona; Maria Teresa Palano; Marzia Barbieri; Elisa Taiana; Elisa Lazzari; Andrea Basile; Mauro Turrini; Anna Pistocchi; Antonino Neri; Raffaella Chiaramonte
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941

Review 10.  The notch ligand JAGGED1 as a target for anti-tumor therapy.

Authors:  Demin Li; Massimo Masiero; Alison H Banham; Adrian L Harris
Journal:  Front Oncol       Date:  2014-09-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.